US OptionsDetailed Quotes
AKBA250516C2000
- 0.37
- 0.000.00%
15min DelayTrading May 13 12:45 ET
0.00High0.00Low
0.00Open0.37Pre Close0 Volume1.23K Open Interest2.00Strike Price0.00Turnover0.00%IV-3.07%PremiumMay 16, 2025Expiry Date0.45Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.61Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Akebia Therapeutics Stock Discussion
•Revenues: Total revenues were $57.3 million in the first quarter of 2025 as compared to $32.6 million in the first quarter of 2024, driven by initial sales of Vafseo in the U.S. and an increase in sales of Auryxia.
▪Vafseo net product revenues were $12.0 million in the first quarter of 2025. Vafseo was launched into the U.S. market in the first quarter of 2025.
▪Auryxia net product revenues were $43.8 million in the first quarter...
Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment
Akebia Therapeutics: Ec Will Review Chmp Recommendation, Final Decision Expected in About Two Months
No comment yet